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ABSTRACT    1 
Aim: We aimed to develop a standardized chart review method to identify drug-related 2 
hospital admissions (DRA) in older people caused by non-preventable adverse drug reactions 3 
and preventable medication errors including overuse, underuse and misuse of medications: the 4 
DRA adjudication guide.   5 
Methods: The DRA adjudication guide was developed based on design and test iterations with 6 
international and multidisciplinary input in 4 subsequent steps: literature review, evaluation of 7 
content validity using a Delphi consensus technique, a pilot test and a reliability study. 8 
Results: The DRA adjudication guide provides definitions, examples and step-by-step 9 
instructions to measure DRA. A 3-step standardized chart review method was elaborated 10 
including 1) data abstraction, 2) explicit screening with a newly developed trigger tool for DRA 11 
in older people and 3) consensus adjudication for causality by a pharmacist and a physician 12 
using the World Health Organization-Uppsala Monitoring Centre and Hallas criteria. A 15-13 
member international Delphi panel reached consensus agreement on 26 triggers for DRA in 14 
older people. The DRA adjudication guide showed good feasibility of use and achieved 15 
moderate inter-rater reliability for the evaluation of 16 cases by 4 European adjudication pairs 16 
(71% agreement, kappa = 0.41). Disagreements arose mainly for cases with potential underuse.  17 
Conclusions: The DRA adjudication guide is the first standardized chart review method to 18 
identify DRA in older persons. Content validity, feasibility of use and inter-rater reliability were 19 
found to be satisfactory. The method can be used as an outcome measure for interventions 20 
targeted at improving quality and safety of medication use in older people.   21 
 22 
 23 
 24 
 25 
 26 
 27 
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What is already known about this subject 28 
 Drug-related hospital admissions represent a growing patient safety threat in older people. 29 
 Identifying drug-related hospital admissions in older people is complex and there is lack of 30 
a standardized approach to identify drug-related hospital admissions. 31 
What this study adds  32 
 We developed a standardised chart review method to measure drug-related hospital 33 
admissions in older persons.  34 
 Content validity, feasibility of use and inter-rater reliability were found to be satisfactory.  35 
 The method can be used as an outcome measure for interventions targeted at improving 36 
quality and safety of medication use in older people.   37 
 38 
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INTRODUCTION 52 
Adverse drug events (ADEs) are a leading cause of iatrogenic harm globally.[1, 2] A significant 53 
proportion of ADEs results in hospitalisation and these so-called drug-related hospital 54 
admissions (DRA) have serious clinical and economic consequences.[3-6] DRA can result from 55 
non-preventable adverse drug reactions (ADR) or from preventable medication errors.  56 
Older adults have almost a seven-fold increased risk of experiencing a DRA compared to 57 
younger persons due to several risk factors such as multi-morbidity and polypharmacy.[7] 58 
Around 70% of DRA in older people are caused by potentially preventable ADEs mainly 59 
resulting from poor medication adherence and inappropriate prescribing.[8-13] The latter 60 
includes the prescription or use of more drugs than are clinically needed (overuse), the 61 
incorrect prescription or use of drugs that are needed (misuse) and the failure to prescribe or 62 
use drugs that are needed (underuse).[14] Identifying DRA in older people is challenging 63 
because ADEs often present as common geriatric problems such as falls, confusion or renal 64 
impairment which might be due to the ageing process, underlying diseases or medications.[13, 65 
15] 66 
No standardised and validated method to identify DRA in older people exists in the literature. 67 
Yet measuring DRA is potentially an important issue in the light of the World Health 68 
Organisation’s Global Patient Safety challenge on medication-related harm.[2] Studies have 69 
reported DRA prevalence rates ranging from 6% to 50% of all admissions in older adults.[16-20] 70 
The wide variance in prevalence rates is associated with the considerable heterogeneity in 71 
definitions and methods used to identify DRA, the study population and the setting.[20, 21] DRA 72 
identification often relies on a highly subjective and variable process and few attempts have 73 
been made to measure DRA resulting from underuse of medications.[12, 19, 22, 23]   74 
We aimed to develop a standardized chart review method to identify DRAs resulting from ADR, 75 
overuse, misuse and underuse of medications, specific to older people: the DRA adjudication 76 
guide. In this paper we present the developmental pathway of the DRA adjudication guide and 77 
the evaluation of its content validity, feasibility of use and reliability, which are defined as 78 
desirable attributes of a quality measure by the Agency for Healthcare Research and Quality.[24] 79 
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The DRA adjudication guide will be used in 4 European centres to measure the primary 80 
outcome DRA in the OPERAM trial (http://operam-2020.eu) that will assess the impact of a 81 
pharmacotherapy optimisation intervention in 2000 multi-morbid older people. 82 
METHODS  83 
Design  84 
The DRA adjudication guide was developed in 4 subsequent steps: (I) the first draft of the guide 85 
was developed based on literature review; (II) this version was subsequently refined based on 86 
evaluation of content validity by a Delphi expert panel; (III) user-feedback in a pilot test and 87 
(IV) a reliability study (Figure 1). 88 
Literature review 89 
Two literature searches were performed in PubMed by the first author for articles published 90 
between January 1, 1990 and August 1, 2015. Screening of titles and abstracts and data 91 
extraction was performed by the first author.  92 
A first exploratory search aimed to review existing structured ADE or DRA identification 93 
approaches to inform the development of the overall DRA identification strategy. The search 94 
included the following medical subject headings (MeSH): ‘Patient admission’, ‘Drug-related 95 
side effects and adverse reactions’, ‘Quality assurance, Health Care’, ‘Patient outcome 96 
assessment’. Studies published in English, French or Dutch that focused on defining, identifying 97 
and/or characterizing ADE or DRA in the adult in-hospital setting were included.  98 
A second literature search aimed to review common causes for DRA in older people to inform 99 
the development of a trigger tool for DRA in older people for inclusion in the DRA adjudication 100 
guide. To improve efficiency and to standardize identification of ADEs, trigger-based chart 101 
review has been advocated as the premier ADE identification approach.[25-27] Triggers are 102 
defined as ‘occurrences, prompts or flags’ found upon chart review that ‘trigger’ further 103 
investigation to determine the presence or absence of an adverse event.[28] Trigger tools have 104 
been designed for a variety of clinical settings but to our knowledge, no trigger tool for 105 
identifying DRA in older people exists. To compile a preliminary trigger tool, the second 106 
literature search aimed to identify common causes for DRA in older people and to review 107 
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previously developed adverse event triggers tools designed for other settings. PubMed was 108 
searched using the following search terms and/or combinations: ‘Aged’[MeSH], ‘Drug-Related 109 
Side Effects and Adverse Reactions’[MeSH], ‘Hospitalization’[MeSH], ‘Trigger’[All fields], 110 
‘Adverse drug events trigger tool’[All fields], ‘Pharmaceutical preparations’[MeSH], 111 
‘Underuse’[All fields], ‘Prescribing omission’[All fields]. Studies on hospitalizations in people 112 
aged ≥65 years resulting from preventable ADEs and non-preventable ADRs were included. 113 
Studies on the development or evaluation of adverse event trigger tools designed for other 114 
settings were also included. Studies on DRA in patients younger than 65 years were excluded. 115 
Trigger tool studies focusing on specific patient groups such as surgical patients were also 116 
excluded.   117 
A data extraction form was developed to document study characteristics including study aims, 118 
population, design, setting, methods used to detect ADE or DRA, causality algorithms used, 119 
professionals involved in ADE or DRA assessment, most frequent causes of DRA, most frequent 120 
medications involved or omitted in DRA, triggers and their positive predictive value.     121 
Evaluation of content validity 122 
Content validity refers to the relationship between an instrument’s content and the construct 123 
it is intended to measure.[29] In the absence of a gold standard to measure DRA, content validity 124 
of the DRA adjudication guide was assessed by an expert panel.  125 
First, the overall DRA identification method suggested by the guide was agreed on a consensus 126 
basis through face-to-face discussions by 3 physicians (BB, JBB, JD) and 2 clinical pharmacists 127 
(AS, OD) with expertise in geriatric pharmacotherapy and medication safety. 128 
Secondly, a 2-round online modified Delphi survey using LimeSurvey® software was conducted 129 
to validate the triggers derived from the literature review. The Delphi method is a consensus 130 
technique that is widely used for questions addressing medication safety in older adults.[30] A 131 
modified online 2-round Delphi survey was selected in this study as a way to combine scientific 132 
rigor and pragmatism to obtain consensus from a geographically diverse expert panel. Experts 133 
were selected based on their recognised academic or clinical expertise on the subject of drug-134 
related morbidity in older patients or were personal contacts. Of the 29 experts invited, 135 
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respectively 15 and 14 experts from 8 different countries took part in the first and second 136 
Delphi round (Table 1).  137 
The Delphi panel was asked to assess the content validity of the preliminary trigger tool, to 138 
develop consensus on the most relevant triggers and to identify additional triggers. 139 
Furthermore the panel was asked to assess 2 screening questions for non-triggered, 140 
spontaneously detected events. In the first Delphi round participants were asked to rate, for 141 
each of the 29 triggers derived from the literature and for the 2 screening questions the 142 
‘relevance to screen for a DRA in older people’ on a 5-point Likert scale (ranging from 143 
‘absolutely irrelevant’ to ‘absolutely relevant’; relevance was defined as ‘the degree to which 144 
the item comprehensively includes the full scope of the outcome it intends to measure’). A 145 
free-text field was provided for each item, allowing comments to improve the trigger design 146 
or to suggest new triggers.  147 
For each item, consensus measurement was based on the median Likert response and the 148 
interquartile range. The following cut-off values of consensus were defined before data 149 
analysis: consensus that a trigger should be retained if the median score on the 5-point Likert 150 
scale was ≥4 and the 25th percentile ≥4 (i.e. ≥75% of the experts considered the trigger as 151 
‘relevant’or ‘absolutely relevant’); consensus that a trigger should be excluded if the median 152 
score was <3 and the 75th percentile <3 (i.e at least 75% of the experts considered the trigger 153 
as ‘irrelevant’ or ‘absolutely irrelevant’); no consensus for triggers that failed to meet either of 154 
the latter cut-off values.   155 
Triggers that were accepted or rejected unanimously after the first round were not presented 156 
in the second round. In the second Delphi round, participants were asked to rate the triggers 157 
for which revisions were suggested in the first round. Furthermore, participants were asked to 158 
re-evaluate the equivocal triggers on the 5-point Likert scale, taking into account the groups’ 159 
responses. Participants were provided with a reminder of their own responses from round 1, 160 
the median group rating and interquartile range and a summary of the comments made by 161 
participants. Equivocal triggers that were rated equivocal again, were not included in the final 162 
trigger tool (Supporting Information S1). 163 
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Pilot test 164 
A pilot test was performed aimed at ensuring that the newly developed DRA adjudication guide 165 
was a workable instrument and to identify points for improvement. For this purpose, the DRA 166 
adjudication guide was piloted independently by a geriatrician and a pharmacist from one 167 
centre (JBB, ST). For the pilot test, 15 cases from a medical record database of frail older patients 168 
admitted to a teaching hospital were randomly selected by using a random number generator. 169 
The reviewers’ suggestions for improvement were discussed within the OPERAM research team 170 
and modifications were subsequently implemented in the DRA adjudication guide.  171 
Reliability study 172 
A reliability study was conducted to assess whether the DRA adjudication guide yields 173 
reproducible results when applied by different raters. Raters were OPERAM research team 174 
members with clinical and/or research experience in geriatric medicine. Pairs of raters in 3 175 
centres (Brussels, Cork and Utrecht) consisted of a pharmacist and physician (SM, FV, IW, AV, 176 
SC, DOM) whereas in 1 centre (Bern) the pair was composed of physicians only (CF, CS). The 177 
raters had no prior experience in using the DRA adjudication guide and were provided with a 178 
video training tutorial (https://www.youtube.com/watch?v=fadmO-WcCHM). 179 
For the purpose of the reliability study, each centre provided 4 cases of multi-morbid older 180 
patients including the discharge and/or admission letter, laboratory values and medication 181 
lists. Translation of the cases was performed by OPERAM research team members from their 182 
mother tongue (Dutch, French, Swiss-German) to English. No formal back-translation process 183 
was undertaken.   184 
Raters were asked to first assess the cases individually and subsequently to come to a 185 
consensus result on the case within the pair. The time needed to adjudicate a case was 186 
recorded. A dichotomous outcome variable (DRA identified yes/no) was defined and inter-rater 187 
reliability was determined by calculating percentage agreement and agreement corrected for 188 
chance between pairs of raters from 4 European centres (Fleiss’ kappa) as well as within each 189 
pair (Cohen’s kappa) for the dichotomous outcome variable. Kappa values were interpreted as 190 
slight agreement if <0.20, fair agreement if 0.21–0.40, moderate agreement if 0.41–0.60, 191 
substantial agreement if 0.61–0.8 and almost perfect agreement if 0.81–1.00.[31] Next, 192 
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adjudication results and discrepancies were shared among all raters, who were asked for 193 
feedback. The primary goal was to determine whether discrepancies were due to difficulties in 194 
using the adjudication method, missed information or case interpretation.  195 
Ethics approval 196 
The ethics committee from the Cliniques universitaires Saint-Luc (Brussels, Belgium) provided 197 
approval for anonymous use of the medical record database (reference number 198 
B403201111806).    199 
RESULTS  200 
Literature review and development of the DRA adjudication guide  201 
Development of the overall DRA identification strategy 202 
Twenty-five studies on ADE or DRA identification were reviewed.[3, 7, 12, 26, 27, 32-51] Chart review 203 
by 2 or more reviewers has been considered as a gold standard in many patient safety studies 204 
because of its high ADE yield and high specificity.[32] To evaluate the relationship between drug 205 
treatment and the occurrence of an adverse event, several causality assessment methods have 206 
been developed. No causality assessment method is universally accepted but expert 207 
judgement is the most widely used.[47] Chart review is however often conducted in an implicit 208 
and unstructured way, resulting in low inter-rater reliability.[32] Our method selected to 209 
adjudicate DRA therefore involved a structured chart review with the aid of a trigger tool to 210 
improve efficiency and standardization in ADE detection.[25] Previous research has 211 
demonstrated that by restricting ADE detection to trigger tools only, whole classes of ADE can 212 
be missed.[32, 52, 53] Therefore two screening questions for non-triggered, spontaneously 213 
detected events were also compiled.  214 
A 3-step approach for DRA identification based on chart review was elaborated (Figure 2). The 215 
3 steps include: 1) abstraction of a standardized list of data from the medical record into an 216 
electronic case report form, the main source documents including the admission and discharge 217 
letter, laboratory values and medication lists; 2) explicit screening for ADE(s) that are potential 218 
DRA with the DRA trigger tool and screening questions for non-triggered events; 3) 219 
adjudication: consensus judgement in terms of ADE causality and ADE contribution to hospital 220 
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admission with the World Health Organisation-Uppsala Monitoring Centre (WHO-UMC) and 221 
Hallas criteria respectively.[36, 54] Steps 2 and 3 are performed by an adjudication pair composed 222 
of a pharmacist and a physician given their complementary knowledge and experience.[55, 56] 223 
Definitions, step-by-step instructions for use and examples are contained in the DRA 224 
adjudication guide (Supporting Information S2). 225 
Development of the trigger tool 226 
Twenty-three studies on common causes of DRA in older people[3, 7-10, 12, 16, 23, 38, 51, 57-69] and 12 227 
trigger tools studies were reviewed.[30, 52, 53, 70-78] Based on the information from the literature 228 
and their own clinical expertise, the research team compiled a preliminary list of 29 triggers 229 
and 2 screening questions for non-triggered events related to ADR, overuse, underuse or 230 
misuse of medications. Key considerations for selecting the triggers were the reported positive 231 
predictive value of the triggers, severity (i.e. the trigger should be severe enough to result in 232 
hospital admission) and ease of detection. The triggers were divided in 3 categories including 233 
diagnoses, abnormal laboratory values and ‘other’ triggers (e.g. antidote use). Each trigger was 234 
elaborated with potential causative drugs or potential causes for drug underuse based on the 235 
STOPP/START criteria version 2 and by consulting pharmacology and pharmacotherapy 236 
references.[79] Consequently, each trigger consists of a diagnosis or abnormal laboratory value 237 
and a corresponding list of potential causative drugs or causes for drug underuse allowing 238 
explicit chart screening for DRA. 239 
Evaluation of content validity 240 
None of the 29 triggers or screening questions were removed at the end of the first round by 241 
the 15-member Delphi panel. Twenty-five triggers and 2 screening questions for non-triggered 242 
events were rated ‘relevant’ or ‘absolutely relevant’ to screen for DRA in older people. Of the 243 
items on which the group agreed, 10 triggers and 2 screening questions were adopted without 244 
alteration in the final tool, whereas 15 triggers were revised according to the participants’ 245 
suggestions. Revisions included changing cut-off thresholds of laboratory values, adding or 246 
removing medications associated with a trigger or adding more detail to the triggers. Four 247 
triggers (theophylline level >20 µg/ml, rash, Clostridium difficile toxin positive stool, neutrophils 248 
<1400/mm³) were rated equivocal. 249 
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After the second round, all 15 triggers with revisions were rated ‘relevant’ or ‘absolutely 250 
relevant’. Three out of 4 equivocal triggers from the first round were rated equivocal again and 251 
these were removed from the trigger tool. The trigger ‘neutrophils <1400/mm³’ was now rated 252 
relevant and was included in the final trigger tool (Supporting Information S1). Following last 253 
refinements, the final 26-item trigger tool was created (Table 2).  254 
Pilot test 255 
The two reviewers involved in the pilot considered the trigger tool as a workable instrument 256 
for screening for DRA. The same sets of triggers were identified by the two reviewers, however 257 
adjudication of DRA was the part where most discrepancies arose. Based on feedback from the 258 
reviewers, the following modifications were made after the pilot:  259 
 The Naranjo algorithm and Therapeutic Failure Questionnaire [63, 80], which were 260 
proposed as causality algorithms in the DRA adjudication guide v.1, were replaced by 261 
the WHO-UMC causality criteria because they reflect clinical practice better. The WHO-262 
UMC criteria were adapted to allow causality assessment due to medication underuse 263 
in line with Klopotowska et al.[32]    264 
 Discharge medications were added to the list of data to abstract to aid in the detection 265 
of potential underuse.  266 
 The DRA identification strategy and instructions for use were adapted to the process 267 
that both reviewers considered as most practical.  268 
Reliability study 269 
Table 3 provides the level of agreement on the presence of a DRA between all centres and 270 
within each pair per centre for 16 cases. The DRA adjudication guide achieved a moderate 271 
inter-rater reliability score between adjudication pairs from 4 European centres (71% 272 
agreement, Fleiss’ kappa = 0.41). Agreement within each pair varied from fair to almost perfect 273 
agreement (69%–94% agreement, Cohens’ kappa = 0.33-0.86). The mean time needed to 274 
assess a case individually was 23±6 minutes and the mean time needed for consensus 275 
discussion was 13±5 minutes.  276 
No differences in inter-rater reliability for DRA identification were observed for triggered and 277 
non-triggered cases. Detailed analysis of the adjudication results showed that in the majority 278 
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of cases the same triggers and potential ADEs were identified but discrepancies arose mainly 279 
on the level of assessment of contribution to hospital admission. Discrepancies arose for 8 280 
cases with more subjective assessments including 5 triggered cases with potential underuse, 2 281 
triggered cases with contributory reasons for admission (i.e. an ADE that is not the main reason 282 
for admission but plays a substantial role in the admission)[36] and 1 case with a non-triggered 283 
DRA (Supporting Information S3).   284 
DISCUSSION  285 
To our knowledge the DRA adjudication guide is the first standardized instrument to identify 286 
DRA in older persons caused by ADR, overuse, underuse and misuse of medications. The DRA 287 
adjudication guide provides definitions, examples and step-by-step instructions to measure 288 
DRA.  289 
DRA identification is based on chart review with the aid of a trigger tool followed by structured 290 
consensus judgement, an approach that has been used successfully in previous ADE studies.[25] 291 
The novelty of our method lies in the development of a trigger tool for DRA, specific to older 292 
people and allowing explicit DRA screening. The DRA adjudication guide calls for a rigorous 293 
evaluation of DRA including triggered and non-triggered events as well as non-preventable 294 
ADR and preventable medication errors, which is the desired broader focus of studying DRA.[21, 295 
32, 52, 53] Furthermore, an adjudication pair composed of a pharmacist and a physician is a 296 
recommended approach for evaluation of ADEs.[55, 56] 297 
To improve safety and quality of care, a valid and practical method to measure and understand 298 
a problem is a critical approach to any patient safety threat.[1, 81, 82] It has been acknowledged 299 
that patient safety measures are often based on insufficient evidence and finding a balance 300 
between scientific soundness and feasibility is a challenge.[81] We addressed these requirements 301 
by utilizing a rigorous developmental pathway based on design and test iterations combining 302 
evidence from published literature with expert opinion and user-feedback from international 303 
and multidisciplinary sources. Content validity, feasibility of use and inter-rater reliability were 304 
found to be satisfactory. 305 
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Despite the development of a standardised procedure, variability in DRA determination 306 
remains. Inter-rater reliability (IRR) between adjudication pairs in 4 European centres was 307 
moderate, which is the most relevant criterion as it is the consensus judgement between the 308 
pharmacist and physician that is of importance. Achieving a good IRR score for ADE 309 
identification is a challenge inherent to retrospective chart review studies, with previous 310 
adverse event studies reporting kappa scores varying from -0.077 to 0.66.[19, 32, 56, 83-85] The 311 
trigger tool allowed to detect the same triggers, yet discrepancies arose mainly on the level of 312 
assessment of contribution to hospital admission. Expert judgement using causality criteria is 313 
not devoid of individual subjective judgements.[47] Exploring the reasons for discrepancies 314 
highlighted the need for further training and standardisation of consensus procedures for more 315 
subjective adjudications such as underuse. For example, 2 out of 4 centres in the present study 316 
considered omission of a statin in a 90-year old patient admitted for myocardial infarction as 317 
a DRA, whereas there is limited evidence of benefit of statins over the age of 80-85.[86]   318 
Our reliability study is the first one evaluating DRA by international adjudication teams, yet 319 
rater pairs only came from 4 European countries. The IRR score can be considered as a 320 
satisfactory result taking into account the following considerations: (i) participants were at the 321 
beginning of their learning curve when IRR was evaluated; (ii) composition of adjudication 322 
teams varied with regards to profession, clinical experience and experience in ADE 323 
identification. It has been shown that IRR among different professions is lower, which explains 324 
the almost perfect agreement score in the team that was composed of only physicians.[56]; (iii) 325 
cases were collected in 4 European hospitals and quality of information in source documents 326 
such as admission and discharge letters therefore varied. Furthermore, translation of cases into 327 
English was needed and was performed by research team members and not by a translation 328 
agency, which might have resulted in differences in case quality. Moreover, interpretation of 329 
cases and source documents from another country where guidelines and practices might vary, 330 
contributes to complexity. However even if the DRA adjudication procedure is applied correctly 331 
by all raters, a certain degree of disagreement is to be expected in adjudication of complex 332 
multi-morbidity cases.  333 
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The following recommendations to optimize IRR will be implemented in the OPERAM trial: (i) 334 
intensification of training and involvement of experienced clinicians in the adjudication teams, 335 
(ii) close monitoring of IRR at different time-points to identify discrepancies and (iii) prompt 336 
feedback and sharing of questions and experiences among teams.[84, 87] 337 
The adjudication guide has several limitations. Firstly, data are collected retrospectively and 338 
hence are limited to the information available in medical charts. For assessment of underuse in 339 
particular, information on patient preferences, life expectancy or adherence are often 340 
undocumented in medical charts.[81] To obtain an accurate picture, prospective identification 341 
of DRA in combination of with patient, caregiver and healthcare professional interviews would 342 
be desirable.[33, 88, 89] Hindsight bias is another limitation of retrospective chart review; knowing 343 
the outcome and its severity may influence the adjudication of causation.[90] Furthermore, the 344 
response rate of the experts invited to the Delphi survey was limited to 48%, nevertheless the 345 
Delphi panel represented various disciplines and countries. Moreover, we did not specify an 346 
age cut-off for older people in the Delphi survey, which might have influenced the outcome. 347 
However in the literature review on which the preliminary list of triggers was based, we only 348 
included studies of patients aged 65 years and older. We therefore believe that our trigger tool 349 
is broad enough to trigger DRA in people aged 65 years and older, which corresponds to the 350 
World Health Organization’s age cut-off to define older people. Finally, we did not compare 351 
the adjudication results from the 4 teams with a gold standard such as adjudication by an 352 
expert panel. 353 
The DRA adjudication guide is time-consuming for use in clinical practice and is designed for 354 
research purposes. The method may be used to study incidence of DRA or drug-related 355 
emergency department visits or as outcome measure for the evaluation of interventions to 356 
optimize pharmacotherapy in older people.  357 
The performance of the trigger tool for detecting DRA has not yet been evaluated.  A future 358 
study will determine the predictive validity, sensitivity and specificity of the trigger tool to 359 
detect DRA in the OPERAM dataset. An electronic trigger tool with improved specificity 360 
consisting of drug-disease combinations could help identify patients at risk of medication-361 
related harm in electronic patient records.[91]  362 
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TABLES 
Table 1: Characteristics of Delphi panellists  
 Experts 
invited 
n (%) 
Participation 
Round 1 
n (%) 
Participation 
Round 2 
n (%) 
Total  29 (100) 15 (52) 14 (48) 
Profession, area of expertise    
Physician, geriatric medicine 10 (34) 6 (40) 6 (43) 
Physician, internal medicine 8 (28) 2 (13) 2 (14) 
Physician, primary care  1 (3) -  -  
     Pharmacist, geriatric medicine 5 (17) 4 (27) 3 (21) 
Pharmacist, medication safety 5 (17) 3 (20) 3 (21) 
Country    
Belgium  5 (17) 5 (33) 4 (29) 
Canada 1 (3) 1 (7) 1 (7) 
Italy 1 (3) -  -  
Ireland 2 (7) 1 (7) 1 (7) 
France 2 (7) 1 (7) 1 (7) 
Switzerland  4 (14) 2 (13) 2 (14) 
The Netherlands 6 (21) 3 (20) 3 (21) 
United Kingdom 2 (7) 1 (7) 1 (7) 
United States 6 (21) 1 (7) 1 (7) 
Sex    
Female 15 (52) 9 (60) 8 (57) 
Male 14 (48) 6 (40) 6 (43) 
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Table 2: Trigger tool for DRA in older persons 
TRIGGER TOOL TO SCREEN FOR DRUG-RELATED HOSPITAL ADMISSIONS IN OLDER PERSONS 
Trigger on admission up 
to 48h of admission 
Suspected causative drugs or causes for underuse 
Diagnoses  
Fall and/or fracture 
Use of any of the following drugs? 
 Benzodiazepines  
 Non-benzodiazepine hypnotics e.g. zopiclone, zolpidem 
 Antipsychotics 
 Antidepressants 
 Sedating antihistamines 
 Opioids 
 Anticholinergic drugsa  
 Other (Please specify):  
 
Use of any drugs causing orthostatic hypotension? 
 Calcium channel blockers 
 Diuretics 
 α1-receptor blockers 
 Nitrates 
 β-blockers 
 ACE-inhibitors 
 
 Angiotensin receptor blockers  
 Direct renin inhibitors (e.g. aliskiren) 
 Anti-Parkinson drugs  
 Antidepressants (mainly tricyclic)  
 Antipsychotics  
 Gliflozines (SGLT2-inhibitors)   
 Other (Please specify):  
If a fall is caused by hypoglycaemia, look for use of drugs contributing to hypoglycaemia (check trigger hypoglycaemia) 
Underuse of any of the following drugs in patients with known osteoporosis and/or history of fragility fracture(s) and/or Bone 
Mineral Density T-scores of -2.5 or lower in multiple sites? 
 800 IU Vitamin D/day (+ 1000-1200 mg calcium/day if 
dietary intake is  <1200-1000mg/day) 
 Bone anti-resorptive therapy ( e.g. bisphosphonates, 
strontiumranelate,teriparatide, denosumab) 
Underuse of any of the following drugs in patients on corticosteroid therapy ≥ 3 months? 
 800 IU Vitamin D/day (+ 1000-1200 mg calcium/day if 
dietary intake is  <1200-1000mg/day) 
 Bisphosphonates 
Underuse of vitamin D in patients who are housebound and/or experiencing falls or with osteopenia with Bone Mineral 
Density T-score between -1 and -2.5 in multiple sites? 
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Confusion/deliriumb 
 
Use of any of the following drugs? 
 Benzodiazepines  
 Non-benzodiazepine hypnotics e.g. zopiclone, zolpidem 
 Antipsychotics 
 Anti-epileptics 
 Antihistamines (H1- and H2-receptor blockers) 
 Antidepressants 
 
 Opioids 
 Dopaminergic agonists 
 Digoxin  
 Fluoroquinolones (dose adjustment in renal impairment required) 
 Acetylcholinesterase-inhibitors (new onset confusion in 
patients with dementia) 
 Other anticholinergic drugsa (Please specify): 
Abrupt discontinuation/rapid dose reduction of any of the following drugs? 
 Benzodiazepines 
 Non-benzodiazepine hypnotics e.g. zopiclone, zolpidem 
 Corticosteroids 
 Dopaminergic agonists 
 Antidepressants 
 Opioids 
 Lithium 
 Antipsychotics 
 Other (Please specify):  
 
Acute renal impairmentb 
 
 
Use of any of the following drugs?   
 Non-steroidal anti-inflammatory drugs 
 ACE-inhibitors 
 Angiotensin receptor blockers 
 Diuretics 
 Sulphonamides 
 Cephalosporins 
 Quinolones (ciprofloxacin) 
 Aminoglycosides 
 Vancomycin 
 Pentamidine 
 
 Rifampicin 
 Acyclovir, valacyclovir, gancyclovir, valgancyclovir, 
foscarnet, cidofovir 
 Lithium 
 Calcineurin Inhibitors (e.g. cyclosporine, tacrolimus) 
 Cisplatin 
 Radiology contrast medium 
 Amphotericin 
 Bisphosphonates 
 Other nephrotoxic drugs (Please specify): 
 
Dehydration 
Use of any of the following drugs? 
 Diuretics 
 Gliflozines (SGLT2-inhibitors) 
 Laxatives 
 Any drugs causing vomiting 
 Any drugs causing diarrhoea 
 Other (Please specify): 
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Bleedingb  
Use of any of the following drugs? 
 Antiplatelets 
 Vitamin K antagonists 
 Direct oral anticoagulants 
 Unfractionated heparin 
 
 Low molecular weight heparins 
 Selective serotonin reuptake inhibitors 
 Non-steroidal anti-inflammatory drugs 
 Other (Please specify): 
 
 Underuse of proton pump inhibitors prophylaxis while  
- NSAIDs monotherapy (≥ 70 years old) or on concurrent NSAIDs and/or antiplatelets and/or corticosteroids  
- NSAIDs or antiplatelet or corticosteroids monotherapy with a history of peptic ulcer disease/gastrointestinal bleeding while 
on these drugs 
Stroke  
Underuse of any of the following drugs in patients with known chronic atrial fibrillation?  
 Vitamin K antagonists 
 Direct oral anticoagulants (except valvular atrial fibrillation) 
Underuse of adequate antihypertensive therapy?  
* Note: Adequate antihypertensive therapy is defined according to the recommendations for older patients in the 2013 European ESH/ESC guidelines for the management of 
arterial hypertension. 
Underuse of any of the following drugs in patients with history of coronary, cerebral or peripheral vascular disease? 
 Antiplatelets   Statins** (unless end-of-life or > 85 years old) 
**Note: Evidence for statin treatment above the age of 80-85 years is limited and clinical judgement should guide decisions in the very old, taking into account life 
expectancy, serious adverse events, possible drug interactions. Low to moderate intensity statin regimens are recommended. (low: simvastatin 10mg, pravastatin 10-20mg, 
fluvastatin 20-40 moderate: atorvastatin 10-20mg, Rosuvastatin 5-10mg, Simvastatin 20-40mg, pravastatin 40-80 mg,  Fluvastatin 80 mg, Fluvastatin 40 mg BID) 
Thromboembolic event 
(DVT or PE) 
Underuse of adequate anticoagulation?   
 Unfractionated heparin 
 Low molecular weight heparins  
 Direct oral anticoagulants 
 Vitamin K antagonists 
 
(Recurrent) myocardial 
infarction or ischaemic 
disease 
Underuse of cardiovascular secondary prevention? 
 Antiplatelets (unless already anticoagulated) 
 Statins**  (unless end-of-life or > 85 years old) 
 β-blocker/ACE-inhibitor or angiotensin receptor blocker 
/adequate anti-anginal therapy in case of ischaemic 
disease  
Underuse of adequate antihypertensive therapy? * 
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Heart failure exacerbation 
Use of any drugs that could precipitate heart failure exacerbation? 
 Non-steroidal anti-inflammatory drugs 
 Corticosteroids 
 Thiazolidinediones (glitazones) 
 Non-dihydropyridine calcium channel blockers 
(verapamil, diltiazem) 
 Sodium-containing formulations (effervescent, 
dispersible and soluble medications) 
 Other (Please specify):  
Underuse of any of the following drugs? 
 β-blockers¥ 
 ACE-inhibitors¥ 
 Diuretics 
Note:  ¥ β-blocker and ACE-inhibitors in heart failure due to left ventricular dysfunction 
COPD exacerbation 
Use of any drugs that could precipitate COPD exacerbation?  
 Benzodiazepines with acute or chronic respiratory failure 
 Opioids  
 Other (Please specify): 
Underuse of any of the following drugs? 
 Single or dual inhaled bronchodilator therapy i.e. a β2 agonist and/or anticholinergic bronchodilator according to the 
GOLD (Global Initiative for Chronic Obstructive Lung Disease) grade  
Uncontrolled (non-
neuropathic) pain 
Underuse of adequate pain treatment (according to the WHO analgesic ladder)?  
 A strong opioid in moderate to severe pain if 
paracetamol, NSAIDs or weak opioids are not appropriate 
(e.g. because of insufficient pain relief) 
 Short-acting opioids for break-through pain during 
treatment with long acting opioids 
 Other (Please specify):  
 
Gastrointestinal disorders 
(severe diarrhoea, 
vomiting)  
Use of any of the following drugs?  
 Antibiotics 
 Laxatives 
 Selective serotonin reuptake inhibitors 
 Digoxin 
 Cholinesterase-inhibitors 
 
 Opioids 
 Non-steroidal anti-inflammatory drugs 
 Chemotherapy (Please specify): 
 Other (Please specify):  
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Major constipation or 
faecal impaction                 
Use of any of the following drugs? 
 Chronic (stimulant) laxative use 
 Opioids (look for underuse of laxatives with regular 
opioid use) 
 Calcium antagonists (Mainly verapamil) 
 Calcium  
 Oral iron 
 Aluminium antacids 
 Atypical antipsychotics  
 Tricyclic antidepressants 
 Bladder antimuscarinics 
 Other anticholinergic drugsa 
 Other (Please specify):  
Laboratory values 
INR > 5  
Look for evidence of bleeding (see trigger) to determine if an adverse drug event (ADE) has occurred. A raised INR in itself is 
not an ADE.  
Digoxin level > 2ng/ml  
Look for signs or symptoms of digoxin toxicity (bradycardia, nausea, diarrhoea, confusion) to determine if a potential ADE has 
occurred. Not all levels above normal will result in an ADE.  
Hypoglycaemia                 
(blood glucose < 4 mmol/L 
or 72 mg/dl) 
Look for symptoms such as lethargy, tremor, confusion, faintness or administration of intravenous or oral glucose. 
Use of any of the following drugs? 
 Insulin  
 Oral hypoglycaemic agents (except metformin in 
monotherapy) 
 MAO – inhibitors 
 β-blockers (masking symptoms of hypoglycaemia) 
 
Hyperglycaemia  
(blood glucose > 11 
mmol/L or 198 mg/dl)  
Use of any drugs that may cause or worsen hyperglycaemia? 
 Corticosteroids 
 Atypical antipsychotics (mainly olanzapine & clozapine) 
 Thiazide diuretics less frequent 
 β-blockers (except carvedilol and nebivolol) less frequent 
 
 Protease-inhibitors  
 Calcineurin Inhibitors (cyclosporine, sirolimus, 
tacrolimus) 
 Other (Please specify): 
 
In case hyperglycaemia is part of diabetic ketoacidosis or hyperosmolar hyperglycaemic state in a patient, review for 
underuse of insulin or oral hypoglycaemic agents. 
Hyperkalaemia                   
(K+ > 5.5 mmol/L) 
Use of any the following drugs? 
 Intravenous or oral potassium 
 Potassium-sparing diuretics     
 ACE-inhibitors 
 Angiotensin receptor blockers 
 Direct renin inhibitors (e.g. aliskiren) 
 Non-steroidal anti-inflammatory drugs 
 
 Heparins (seldom, mainly when treated > 7days and 
concomitant other risk factors) 
 Trimethoprim-sulfamethoxazole 
 Cyclosporine 
 Tacrolimus 
 Other (Please specify): 
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Hypokalaemia                    
(K+ < 3 mmol/L) 
Use of any of the following drugs? 
 Loop diuretics 
 Thiazide and thiazide-like diuretics  
 Corticosteroids 
 Laxatives 
 Salbutamol (IV or aerosol) 
 Theophylline 
 Other (Please specify): 
Hyponatraemia                
(Na+ < 130 mmol/L) 
Use of any of the following drugs? 
 Diuretics 
 Selective serotonin reuptake inhibitors  
 Tricyclic antidepressants  
 ACE-inhibitors 
 
 Angiotensin receptor blockers 
 Carbamazepine & oxcarbazepine 
 High dose cyclophosphamide 
 Other (Please specify): 
 
White blood cells 
 < 3000 /mm3  or 
 < 3 x 10³/µL 
Use of any of the following drugs?  
 Carbamazepine & oxcarbazepine  
 Antipsychotics ( mainly clozapine)  
 Thyreostatics 
 Ganciclovir 
 Immunosuppressants  
 
 Chemotherapy (Please specify): 
 Mirtazapine (first 6 weeks of treatment) 
 Voriconazole 
 Other (Please specify): 
Platelet count                        
< 50000 /mm3  or  
< 50 x 10³/µL 
Use of any of the following drugs? 
 Carbamazepine & oxcarbazepine 
Ganciclovir 
 Unfractionated heparin 
 Low molecular weight heparins 
 Immunosuppressants 
 Thienopyridines (mainly ticlopidine) 
 Quinine sulfate 
 Sulfamides Less frequent  
 Chemotherapy (Please specify): 
 Other (Please specify): 
 
 Use of any of the following drugs? 
Neutrophils < 1400/mm³ 
or < 1.4 x 10³/µL 
 Ganciclovir 
 Antipsychotics ( mainly clozapine)  
 Thyreostatics 
 Thienopyridines (mainly ticlopidine)  
 Chemotherapy (Please specify): 
 Other (Please specify): 
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Other 
Antidote use or 
treatments that suggest a 
potential ADE 
Use of any of the following drugs on the day of admission? 
 Flumazenil in a patient on benzodiazepines  
 Naloxone in a patient on opioids 
 Phytonadione (vitamin K) in a patient on VKA 
 Protamine sulphate in a patient on heparins 
 Oral or intravenous glucose or glucagon in a patient 
taking hypoglycaemic drugs 
 Potassium supplements in case of hypokalaemia 
 Sodium polystyrene (Kayexalate) in case of 
hyperkalaemia 
 
 Adrenaline, antihistamines and corticosteroids (general 
drug allergy) 
 Acetylcysteine (paracetamol overdose) 
 Digoxin antibodies in a patient with supratherapeutic 
digoxin levels 
 Oral metronidazole or vancomycin in a patient who has 
recently been treated with an antibiotic that may cause 
Clostridium difficile associated diarrhoea 
Mention of a (potential) 
ADE in the medical record  
Assess causality using the WHO-UMC criteria 
Abrupt medication stop 
within 24h of admission 
When medications are stopped or withheld as compared to medications taken at home, look for reasons why this was done. 
Abruptly stopping medications is a trigger requiring further investigation for cause. A sudden change in patient condition 
requiring adjustment of medications is often related to an ADE. 
ADE, adverse drug event; ADR, adverse drug reaction; COPD, chronic obstructive pulmonary disease; DVT, deep vein thrombosis; FEV1, forced expiratory volume in 1 second; ESH/ESC, European Society of 
Hypertension/European Society of Cardiology; INR, international normalised ratio, NSAIDS, non-steroidal anti-inflammatory drugs; PE, pulmonary embolism; VKA, Vitamin K antagonists  
aA list of medications with clinically relevant anticholinergic properties is available in the DRA adjudication guide; bDetailed definition of trigger available in the DRA adjudication guide  
SCREENING QUESTIONS FOR NON-TRIGGERED, SPONTANEOUSLY DETECTED EVENTS 
1. Could the main or contributory reason for admission be related to a drug or recent change in medications?  
 Adverse drug reaction (non-preventable side effect, first allergic reaction) 
 Overuse of medication(s) (drug without an indication, too long duration 
of therapy, therapeutic duplication) 
 Inappropriate discontinuation (removal or dosage decrease) leading to 
physiological withdrawal signs/symptoms or return of the underlying 
disease signs/symptoms 
 Wrong drug 
 Wrong dose (supratherapeutic or subtherapeutic) 
 Clinically significant drug-drug or drug-food interactions 
 Inappropriate monitoring 
 Other (e.g. drug not correctly dispensed/prepared/administered) 
2. Could the main or contributory reason for admission be related to underuse?  
 Omission of an indicated drug 
 Too short duration of medication therapy 
 Suspected adherence concerns 
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Table 3: Inter-rater reliability for DRA presence between 4 adjudication pairs and per centre 
for the evaluation of 16 cases. *Respectively Fleiss’ and Cohen’s kappa were calculated to  
determine the level of agreement between the 4 adjudication pairs and within each centre. 
 
Raters % Agreement Kappa* 
4 adjudication pairs 71% 0.41 
Centre 1 (2 physicians) 94% 0.86 
Centre 2 (physician + pharmacist) 75% 0.42 
Centre 3 (physician + pharmacist) 69% 0.33 
Centre 4 (physician + pharmacist) 88% 0.74 
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